BB
Therapeutic Areas
Breakthru Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead Program (undisclosed) | Aggressive Solid Tumors | Pre-clinical |
Leadership Team at Breakthru Medicine
SP
Steve Potts, PhD, MBA
Chief Executive Officer
MM
Mark Mulvihill, PhD
Chief Science Officer
MG
Mark Gergen
Board Chair